OncoMune Publishes Positive Results Of OCM-8054 - Breast Cancer Dependency On BORIS U

[News]

OncoMune LLC, a biotechnology company focused on developing targeted cancer therapeutics, announced the publication of its preclinical OCM-8054 data. The publication entitled, "Selective apoptosis of breast cancer cells by siRNA targeting of BORIS," appeared in the May 23rd 2008 issue of the scientific journal, Biochemical and Biophysical Research Communications, Volume 370, Issue 1, Pages 109-112.

More... (http://www.medicalnewstoday.com/articles/120422.php)